TENX Financials Tenax Therapeutics, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0 | -$53M | — | — | -54.2% | -50.5% | — | — | $98M |
| 2024 | $0 | -$18M | — | — | -19.1% | -18.2% | — | — | $95M |
| 2023 | — | -$8M | — | — | -95.1% | -65.9% | — | — | $10M |
| 2022 | — | $11M | — | — | 740.0% | 324.5% | -$11M | — | $2M |
| 2021 | — | -$32M | — | — | -765.1% | -541.9% | -$11M | — | $6M |
| 2020 | — | -$10M | — | — | -213.0% | -143.4% | -$9M | — | $6M |
| 2019 | — | -$8M | — | — | -222.5% | -131.9% | -$8M | — | $5M |
| 2018 | — | -$14M | — | — | -120.2% | -106.0% | -$6M | — | $12M |
| 2017 | — | -$9M | — | — | -99.5% | -89.4% | -$12M | — | $2M |
| 2016 | — | -$44M | — | — | -256.3% | -188.2% | -$16M | — | $10M |
| 2015 | — | -$14M | — | — | -20.0% | -17.0% | -$10M | — | $8M |
| 2014 | — | -$20M | — | — | -23.6% | -20.9% | -$9M | — | $58M |
| 2014 | — | -$127M | — | — | -417.9% | -373.1% | -$65M | — | $6M |
| 2013 | — | -$123M | — | — | -4305.4% | -2815.6% | -$63M | — | $3M |
| 2013 | — | -$119M | — | — | -10555.4% | -2025.7% | -$61M | — | $4M |
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $0 | -$18M | — | — | -15.7% | -14.6% | — | — | $118M |
| Mar '26 | $0 | -$16M | — | — | -13.7% | -12.8% | — | — | $119M |
| Dec '25 | $0 | -$16M | — | — | -16.0% | -14.9% | — | — | $98M |
| Sep '25 | $0 | -$16M | — | — | -16.4% | -15.4% | — | — | $99M |
| Jun '25 | $0 | -$11M | — | — | -10.5% | -10.2% | — | — | $106M |
| Mar '25 | $0 | -$10M | — | — | -9.5% | -9.3% | — | — | $111M |
| Dec '24 | — | -$6M | — | — | -6.8% | -6.5% | — | — | $95M |
| Sep '24 | — | -$4M | — | — | -4.1% | -4.0% | — | — | — |
| Jun '24 | — | -$4M | — | — | -40.3% | -33.7% | — | — | — |
| Mar '24 | — | -$4M | — | — | -30.6% | -26.3% | — | — | — |
| Dec '23 | — | -$12M | — | — | -150.6% | -104.4% | — | — | $10M |
| Sep '23 | — | $2M | — | — | 17.5% | 16.6% | — | — | — |
| Jun '23 | — | -$1M | — | — | -8.4% | -7.9% | -$924568 | — | $13M |
| Mar '23 | — | $1M | — | — | 9.9% | 9.2% | -$2M | — | $14M |
| Dec '22 | — | $3M | — | — | 170.7% | 74.9% | -$2M | — | $2M |
| Sep '22 | — | $3M | — | — | 73.8% | 61.5% | -$3M | — | $4M |
| Jun '22 | — | -$3M | — | — | -42.2% | -34.2% | -$3M | — | $7M |
| Mar '22 | — | $3M | — | — | 169.4% | 72.8% | -$3M | — | $3M |
| Dec '21 | — | -$62M | — | — | -1454.5% | -1030.3% | -$3M | — | $6M |
| Sep '21 | — | $4M | — | — | 52.5% | 42.6% | -$3M | — | $8M |
Valuation over time
How the market has priced TENX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 121.3× (Mar '23) to 71.3× (Dec '23).
Frequently asked questions
Is TENX growing its revenue and profit?
See the revenue and net-income charts above for Tenax Therapeutics, Inc.'s multi-year trend.
How much debt does TENX have?
As of FY2025, Tenax Therapeutics, Inc. reported — of total debt against $98M of cash.
What is TENX's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
What is TENX's P/E ratio?
As of Sep '26, Tenax Therapeutics, Inc. traded at a price-to-earnings ratio of about 71.3× (market cap ÷ latest annual net income). The valuation charts above show how its P/E have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.